Shares of Repligen Corp. (RGEN) surged 6.5% after the company posted third-quarter 2024 adjusted earnings per share of $0.43, surpassing the Zacks Consensus Estimate of $0.34.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
•
•
•
•
•
•
•
•
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
zacks.com
25%
Finnhub
25%
Yahoo
25%
Others
25%
Country
US
Industry
Health Care
Market Cap
Mid Cap
Num. Employees
2025
IPO Date
Apr 29, 1986
Country
US
Industry
Health Care
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,025 full-time employees. The firm's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data
+2.78% more bullish
compared to last week
Related Stocks
Related Stocks
Stocks being mentioned with RGEN